Prostate Cancer News on BioPortfolio

Toxicity From AllGrade AEs in Prostate CA Better Reflects QOL

TUESDAY Jan. 8 2019 In prostate cancer patient and clinicianbased cumulative toxicity scores comprising allgrade adverse events AEs better reflect the impact on patient quality of life QoL than scores comprising highgrade AEs only...

2019 Brings Updated Thoughts about Corcept & More

With the turbulence in Corcepts CORT valuation and the overall market we fielded requests to address both issues. After the recent issuance of a patent CORT climbed up to $17.63 on December 13 2018. It descended to $11.80 on December 21 and about a week la...

Pages